Pharmacyclics PCYC-1121-CA A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Cancer - Lymphoma
Principal Investigator: Nalini Janakiraman, MD
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
Diagnosis of marginal zone lymphoma (including splenic, nodal, and extranodal sub-types); previously received one or more lines of therapy including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least partial response or documented progressive disease after the most recent systemic treatment regimen; at least 18 years of age.